Vanquish Oncology Inc. (Vanquish)

Oncology Corporate Profile

HQ Location

2001 S. First Street, Ste. 201
Champaign, IL 61820

Company Description

Vanquish Oncology is focused on developing targeted, small molecule oncology therapeutics for unmet or underserved cancer markets. Vanquish currently has an advanced program in selectively triggering cancer cell death through activating procaspase 3, a key late-stage effector of apoptosis. Vanquish is developing procaspase 3 activators as orally delivered therapies through a capital efficient virtual model that leverages contract research and manufacturing to minimize infrastructure outlays and overhead.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PAC-1procaspase activating compound-1Various cancer typesI


Recent News Headlines

There are no news items to display